Rabeprazole Sodium Tablet, Delayed Release
Product Images NDC 76420-223

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Rabeprazole Sodium (NDC 76420-223). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Asclemed Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Image (Rabeprazole Dr Tablet 01)

Chemical structure diagram of rabeprazole sodium, showing the molecular arrangement of atoms including sodium, sulfur, nitrogen, oxygen, and carbon in the compound.*

FDA Label Image

Figure 2: Mean Daytime Heartburn Scores Rab-usa-2 (Rabeprazole Dr Tablet 02)

A line chart depicting mean heartburn scores over a 28-day study period for three groups: placebo, 10 mg rabeprazole sodium (RAB), and 20 mg rabeprazole sodium. The x-axis represents study days from -14 to 28, and the y-axis shows mean heartburn scores ranging from 0 (none) to 4 (very severe). The graph indicates changes in heartburn severity before and after the study start (day 0) for each group.*

FDA Label Image

Figure 3: Mean Nighttime Heartburn Scores Rab-usa-2 (Rabeprazole Dr Tablet 03)

A line chart showing mean heartburn scores over a 28-day study period comparing placebo, rabeprazole 10 mg, and rabeprazole 20 mg groups. The x-axis represents study days from -14 to 28, and the y-axis represents mean heartburn scores from 0 (none) to 4 (very severe). Trends indicate changes in heartburn severity across treatment groups over time.*

FDA Label Image

Figure 4: Mean Daytime Heartburn Scores Rab-usa-3 (Rabeprazole Dr Tablet 04)

A line graph comparing mean heartburn scores over days for two groups: placebo (n=58) and rabeprazole sodium 20 mg (n=59). The x-axis represents study days from -14 to 28, and the y-axis shows mean heartburn scores from 0 (none) to 4 (very severe). The graph shows a decrease in heartburn scores for the rabeprazole group after day 0 compared to placebo.*

FDA Label Image

Figure 5: Mean Nighttime Heartburn Scores Rab-usa-3 (Rabeprazole Dr Tablet 05)

A line graph showing mean heartburn scores over a 28-day study period comparing placebo and RAB 20 mg groups. The x-axis represents study days from -14 to 28, and the y-axis shows mean heartburn scores from 0 (none) to 4 (very severe). Both groups show decreasing scores over time, with RAB 20 mg consistently lower than placebo.*

FDA Label Image

Rabeprazole Dr Tablets (Rabeprazole Dr Tablet Label)

Labels for Rabeprazole Sodium DR Tablets 20 mg from Enovachem Pharmaceuticals include multiple versions indicating packaging and relabeling. The labels show quantities of 30, 60, and 90 tablets. The labels also include NDC numbers (76420-223-30, 76420-223-60, and 76420-223-90), distributor Advagen Pharma Ltd., and details such as batch number, lot number, and storage instructions at controlled room temperature.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.